TMRDC Banner

pharma market research - the original one-stop pharmaceutical information shop

PHARMA MARKET RESEARCH STUDIES


Global Pharmaceutical Biotech Market 2010-2025


World Smoking-Cessation Drug Market 2010-2025


Oncology Market Leaders – Analyses and Outlook – 2010-2025


Oncology Market Leaders – Analyses and Outlook – 2010-2025


World Ophthalmic Pharmaceutical Market 2010-2025


Anti-aging Products and Services: The Global Market


Healthcare Information Technology


2008/2009 Healthcare Research Review



Cord Blood Registry Files Suit Against ViaCell and Viacord for Misleading Advertising


News Article
Published: March 2005
Sector: Press Release

SAN BRUNO, Calif., March 2 /PRNewswire/ -- Cbr Systems, Inc. (Cord Blood Registry), the leading provider of services for the storing and processing of newborn cord blood stem cells, announced today that it has filed a complaint against ViaCell, Inc. (NASDAQ:VIAC) and its wholly owned subsidiary Viacord, Inc. for false and misleading advertising and related unlawful conduct. The complaint, filed on February 25, 2005 in the Federal District Court in San Francisco, alleges that ViaCell and Viacord have disseminated and continue to disseminate false and misleading advertising to the public in an effort to promote their umbilical cord blood stem cell preservation services. Cord blood banking is a process that allows parents to have the stem cells from a newborn's cord blood saved for potential future medical uses.

"Cord Blood Registry is the leader in this fast-growing market and enjoys a position of being the world's largest family cord blood bank with triple-digit-growth in recent periods," says Stephen M. Grant, Vice President of Communications for CBR. "We have spent a decade building a strong reputation of trust and are highly recommended by the nation's leading obstetricians for cord blood stem cell services. Viacord's unfounded claims in these areas are damaging to the CBR brand and misleading to consumers." Additional false statements made by Viacord regarding their pricing and consumer guarantee, as well as unsubstantiated claims about their cell recovery rates and storage systems, are among other complaints named in the lawsuit.

CBR filed a complaint in the Federal Court as a final step to gain compliance from Viacord in correcting the misleading and untruthful statements to physicians and consumers in their marketing materials. "Although we would have preferred to handle this outside of the legal system, Viacord failed to correct the information in a timely and effective manner," says Grant.

This press release is provided in good-faith by Chiltern Magazine Services Ltd ("CMS") as a service to users. Whilst every care is taken in sourcing and preparing material included here, any error or incorrect content cannot form the basis for any legal action against the site-owner. Users are advised to check the accuracy of any statements before relying upon them. Likewise, any forward-looking statements made by the author of the press release should be treated as such.

For full details, please email keithw@cmsinfo.com

Home | About | Terms | Privacy


Office Address: Chiltern Magazine Services Ltd., P&A House, Chesham, Bucks. HP5 3HB, England.

Telephone: UK +44 (0) 1494 771734 Fax: +44 (0) 01494 778994 e-mail: keithw@cmsinfo.com

Telephone: USA +(1) 508 861 0401 Fax: +(1) 508 861 0401

Registered Office: 2a Altons House Office Park, Gatehouse Way, Aylesbury, HP19 3XU, UK

Registered in England and Wales No. 3240740 VAT No. GB 685 4343 10

CMSInfo (Chiltern Magazine Services Ltd.) is a company registered at Companies House in England and Wales (Company No. 3240740).
CMSInfo is also registered in accordance with the Data Protection Act 1998 (registration number R0094104).
Terms and Conditions